Zhong Guo Jing Ji Wang·2026-01-30 08:38Core Viewpoint - The actual controller of Zhaoyan New Drug, Zhou Zhiwen, has terminated his plan to reduce shareholdings in the company, having sold a total of 14,979,000 shares within a specified period, resulting in significant cash proceeds. Group 1: Shareholding and Reduction Plan - Zhou Zhiwen held 74,725,981 shares before the reduction plan, representing 9.9704% of the total share capital [1] - The reduction plan was first disclosed on December 30, 2025, allowing for a maximum reduction of 14,980,000 shares, which is 20.0466% of his holdings and 1.99873% of the total share capital [1] - The actual reduction occurred from January 22 to January 28, 2026, with a total of 14,979,000 shares sold [2] Group 2: Financial Details of the Reduction - The shares were sold at a price range of 34.78 to 42.19 yuan per share, resulting in total proceeds of 567,606,657.9 yuan [1][2] - The reduction was completed with only 1,000 shares remaining unsold, achieving a reduction ratio of 1.99894% [2] - Following the reduction, Zhou Zhiwen's remaining shareholding is 59,746,981 shares, which is 7.9732% of the total share capital [2] Group 3: Historical Context - Since November 5, 2020, Zhou Zhiwen has cumulatively reduced his holdings by 14,113,200 shares, realizing approximately 915 million yuan in cash [2] - The actual controllers of Zhaoyan New Drug are identified as Feng Yuxia and Zhou Zhiwen, a couple [3]